The answer comes down to one key tactic: negotiation.
Both companies are under pressure to improve their performance.
The idea is that transparency would lead to more competition and lower costs. One drug company is already on board.
Pharmacy chain Walgreens reported a 3.8 percent drop in sales for the quarter. The company cited a weak cough, cold and flu season — and declining profits from generic and branded prescription drugs. Click the audio player above to hear the full story.
Senior leaders of big pharmaceutical companies are in D.C. Tuesday to testify before a Senate committee.
Bristol-Myers Squibb announced Thursday that it’s going to acquire another drugmaker, Celgene. The deal is worth about $74 billion. The combined company will have nine products with sales of more than a billion dollars a year, including some blockbuster cancer drugs. The merger is a sign that Big Pharma is betting big on cancer medications. […]
“They blame me for capitalism,” said Martin Shkreli.
Will drug companies agree to the president's proposal?
The European Union has some 20 "biosimilar" generics on the market; the US has one.